echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Ruiyang pharmaceutical "Viagra" generic drug approved by FDA

    Ruiyang pharmaceutical "Viagra" generic drug approved by FDA

    • Last Update: 2017-04-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: drug magic cube 2017-04-26 according to the US drug library, on April 21, Ruiyang pharmaceutical sildenafil citrate tablets (25mg, 50mg, 100mg) obtained FDA tentative approval FDA's provisional approval means that the quality, safety and effectiveness of the drug have met the standards for listing in the United States after examination However, due to patent rights and / or exclusivity, it is temporarily unable to be listed and sold in the United States Sildenafil citrate, the famous Viagra, is the first oral drug developed by Pfizer to treat erectile dysfunction (ED) Its peak sales in 2012 were about $2 billion At present, 11 enterprises such as Teva, Apotex, mylan, Watson, etc have listed the imitation products of sildenafil citrate tablets (20mg) Pfizer's "Viagra" sales volume is in China In addition to Pfizer, the original research enterprise of sildenafil citrate tablets, there are two generic drugs approved, namely Baiyunshan (50mg) and Jiangsu Yabang Epson Pharmaceutical (50mg, 100mg), with 19 Enterprises under research Among them, Baiyunshan, as the first imitation manufacturer of Viagra, has seen a rapid increase in sales since its listing in 2014, reaching 400 million yuan in 2016 (see: the sales of Jinge, the outbreak of second birth concept drugs, Baiyunshan's total revenue in 2016 exceeded 20 billion yuan) Domestic application and approval of sildenafil citrate sales source of "Jinge" in Baiyunshan: Medical magic cube sales database, click the menu on the home page for free query As previously described by the medicine Rubik's cube, there is a chance for the generic drugs listed in the United States to overtake in the domestic generic consistency evaluation (see: stone medicine and Hengrui are out of the game, and the time left for metformin may not be long) It is not clear whether Ruiyang pharmaceutical will take advantage of foreign countries to kill back at home this time.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.